Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$110.66 USD

110.66
172,012

+0.34 (0.31%)

Updated Jul 29, 2024 11:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Value Investors Consider Novartis (NVS) Stock Now?

by Zacks Equity Research

Let's see if Novartis (NVS) stock is a good choice for value-oriented investors right now from multiple angles.

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.

Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties

by Zacks Equity Research

Incyte's (INCY) earnings miss, but revenues surpass estimates in the fourth quarter on higher royalty revenues and increased Jakafi sales.

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

by Zacks Equity Research

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.

Roche's (RHHBY) 2021 Earnings, Sales Grow on COVID-19 Tests

by Zacks Equity Research

Roche (RHHBY) performance in the fourth quarter and 2021 was encouraging, driven by demand for COVID-19 tests and recovery in pharma sales. However, sales are expected to slow down in 2022.

Incyte (INCY) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

by Zacks Equity Research

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Indrajit Bandyopadhyay headshot

Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO

by Indrajit Bandyopadhyay

Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.

Daniel Laboe headshot

Buyers Come In With A Penchant For Growth After Short Market Correction

by Daniel Laboe

This week's riveting earnings line-up promises to be chalked full of enlightening quarterly reports from leading corporations across sectors

Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer

by Zacks Equity Research

The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.

Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.

Glaxo (GSK) Stock Down As Unilever Decides Not to Raise Offer

by Zacks Equity Research

Unilever decides that it will not raise its offer of $68 billion for Glaxo's (GSK) Consumer Healthcare business.

Ionis' (IONS) Partner to Begin New Huntington's Disease Study

by Zacks Equity Research

Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

Glaxo (GSK) Rejects Unilever's $68B Bid for Consumer Business

by Zacks Equity Research

Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.

Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug

by Zacks Equity Research

Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.

Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies

by Zacks Equity Research

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.

Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis

by Zacks Equity Research

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung

by Zacks Equity Research

Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs

by Kinjel Shah

FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).

Novartis (NVS) Gets FDA Nod for Cosentyx's Label Expansion

by Zacks Equity Research

The FDA approves Novartis' (NVS) Cosentyx for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis.

Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA

by Zacks Equity Research

Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

by Zacks Equity Research

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Ionis (IONS) Collaborates With AstraZeneca for Eplontersen

by Zacks Equity Research

Ionis (IONS) and AstraZeneca (AZN) are set to have joint development and commercialization rights of eplontersen in the United States. AstraZeneca will have exclusive rights to commercialize it in the rest of the world.